Please ensure Javascript is enabled for purposes of website accessibility

Pfizer to Develop mRNA Vaccines Without BioNTech

By Cory Renauer - Mar 23, 2021 at 2:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

Pfizer's (PFE 3.59%) success in developing an effective COVID-19 vaccine in record time has given the pharmaceutical giant the confidence to invest heavily in the technology that underpins that vaccine. In an interview with The Wall Street Journal on Tuesday, CEO Albert Bourla revealed that Pfizer plans to become a leader in the development of new vaccines that rely on messenger RNA (mRNA).

Unfortunately for BioNTech (BNTX -2.90%), those plans don't rely on a continuation of the collaboration agreement that brought the world its first authorized mRNA-based vaccine. According to Bourla, Pfizer doesn't need to work with BioNTech anymore because it has the expertise to develop those new vaccines on its own.

Scientist working alone in a lab.

Image source: Getty Images.

Pfizer still has options to license two more BioNTech vaccines, one directed against cytomegalovirus (CMV) and another meant to prevent respiratory syncytial virus (RSV). Despite a great deal of effort over the past 50 years, there still aren't any effective vaccines approved to protect against those viruses. 

If Pfizer can rapidly develop new mRNA vaccines as Bourla suggests, it's easy to see why the company would rather strike out on its own. Pfizer and BioNTech are splitting the profits on BNT162b2 evenly at the moment. It's hard to say how much will hit their bottom lines, but the partners expect sales of the COVID-19 vaccine to reach around $15 billion this year.

If it turns out that annual booster shots are not needed, coronavirus vaccine sales could taper off significantly before the end of 2022, then dwindle to nearly nothing by 2024. BioNTech will have plenty of cash to fund the development of new mRNA drugs on its own, but competing with Pfizer will be a challenge. Bourla also said Pfizer intends to apply recently learned lessons to develop new mRNA vaccines at a blistering pace in the future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.47 (3.59%) $1.82
BioNTech SE Stock Quote
BioNTech SE
BNTX
$163.00 (-2.90%) $-4.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.